Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes

This publication has 14 references indexed in Scilit:

• Fluctuation of Serum Basal Insulin Levels Following Single and Multiple Dosing of Insulin Glargine
  Diabetes Technology & Therapeutics, 2006
• Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes
  Diabetic Medicine, 2006
• Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique
  Diabetologia, 2005
• Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin
  Diabetic Medicine, 2004
• Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
  Diabetes, 2004
• Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers
  Diabetes & Metabolism, 2003
• Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime
  Diabetes Care, 2003
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
  Diabetes, 2000
• Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
  Diabetes Care, 2000
• Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
  Diabetes Care, 2000